PortfoliosLab logo

Adaptimmune Therapeutics plc (ADAP)

Equity · Currency in USD · Last updated Mar 21, 2023

Share Price Chart


Loading data...

Performance

The chart shows the growth of $10,000 invested in Adaptimmune Therapeutics plc in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $681 for a total return of roughly -93.19%. All prices are adjusted for splits and dividends.


0.00%50.00%100.00%NovemberDecember2023FebruaryMarch
0.89%
7.43%
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ADAP

Adaptimmune Therapeutics plc

Popular comparisons: ADAP vs. SCHD

Return

Adaptimmune Therapeutics plc had a return of -25.34% year-to-date (YTD) and -50.00% in the last 12 months. Over the past 10 years, Adaptimmune Therapeutics plc had an annualized return of -28.95%, while the S&P 500 had an annualized return of 8.51%, indicating that Adaptimmune Therapeutics plc did not perform as well as the benchmark.


PeriodReturnBenchmark
1 month-36.26%-3.13%
Year-To-Date-25.34%2.92%
6 months-28.76%2.02%
1 year-50.00%-11.46%
5 years (annualized)-36.31%7.79%
10 years (annualized)-28.95%8.51%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202328.08%-5.35%
2022-45.71%32.09%52.82%-32.72%

Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Adaptimmune Therapeutics plc Sharpe ratio is -0.53. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


-1.00-0.80-0.60-0.40-0.20NovemberDecember2023FebruaryMarch
-0.53
-0.45
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

Dividend History


Adaptimmune Therapeutics plc doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%NovemberDecember2023FebruaryMarch
-94.84%
-17.62%
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Adaptimmune Therapeutics plc. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Adaptimmune Therapeutics plc is 96.57%, recorded on Nov 15, 2019. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.57%Jun 17, 20151114Nov 15, 2019
-14.05%May 8, 201517Jun 2, 20157Jun 11, 201524

Volatility Chart

Current Adaptimmune Therapeutics plc volatility is 66.59%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


0.00%50.00%100.00%150.00%NovemberDecember2023FebruaryMarch
66.59%
20.82%
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)